(TBPH) Theravance Biopharma - Overview
Exchange: NASDAQ •
Country: United States •
Currency: USD •
Type: Common Stock •
ISIN: KYG8807B1068
Stock: COPD, Nebulizer, Norepinephrine, Hypotension, MSA
Total Rating 41
Risk 36
Buy Signal 0.61
EPS (Earnings per Share)
Revenue
| Risk 5d forecast | |
|---|---|
| Volatility | 40.9% |
| Relative Tail Risk | -14.7% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 1.72 |
| Alpha | 103.43 |
| Character TTM | |
|---|---|
| Beta | 0.473 |
| Beta Downside | 0.252 |
| Drawdowns 3y | |
|---|---|
| Max DD | 35.74% |
| CAGR/Max DD | 0.67 |
Description: TBPH Theravance Biopharma December 26, 2025
Theravance Biopharma Inc. (NASDAQ:TBPH) is a U.S.-based biopharmaceutical company that markets YUPELRI, a once-daily nebulized long-acting muscarinic antagonist for chronic obstructive pulmonary disease (COPD), and is advancing Ampreloxetine, a once-daily norepinephrine reuptake inhibitor, in late-stage trials for neurogenic orthostatic hypotension associated with Multiple System Atrophy. The firm commercializes YUPELRI through a strategic collaboration with Viatris Inc. and has been publicly traded since its incorporation in 2013.
Key recent metrics: YUPELRI generated approximately $115 million in net sales in FY 2023, reflecting a 12% year-over-year growth driven by expanding COPD prevalence in an aging U.S. population. Theravance reported a cash runway of roughly $250 million at year-end, supporting continued R&D on Ampreloxetine and pipeline diversification. Industry-wide, biotech firms are benefiting from a 7% CAGR in the global COPD therapeutics market and a favorable FDA “breakthrough therapy” pathway that can accelerate time-to-market for novel neuro-vascular drugs.
For a deeper dive into TBPH’s valuation and risk profile, consider checking out ValueRay’s analyst overview.
Piotroski VR‑10 (Strict, 0-10) 4.0
| Net Income: 29.3m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.59 > 0.02 and ΔFCF/TA 62.06 > 1.0 |
| NWC/Revenue: 395.0% < 20% (prev 147.2%; Δ 247.8% < -1%) |
| CFO/TA 0.59 > 3% & CFO 243.7m > Net Income 29.3m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 9.48 > 1.5 & < 3 |
| Outstanding Shares: last quarter (51.9m) vs 12m ago 5.85% < -2% |
| Gross Margin: 60.89% > 18% (prev 0.42%; Δ 6046 % > 0.5%) |
| Asset Turnover: 20.82% > 50% (prev 17.75%; Δ 3.08% > 0%) |
| Interest Coverage Ratio: -11.01 > 6 (EBITDA TTM -25.8m / Interest Expense TTM 2.52m) |
Altman Z'' -7.99
| A: 0.76 (Total Current Assets 354.7m - Total Current Liabilities 37.4m) / Total Assets 415.5m |
| B: -2.22 (Retained Earnings -920.7m / Total Assets 415.5m) |
| C: -0.07 (EBIT TTM -27.8m / Avg Total Assets 385.8m) |
| D: -5.04 (Book Value of Equity -920.6m / Total Liabilities 182.8m) |
| Altman-Z'' Score: -7.99 = D |
Beneish M -4.00
| DSRI: 0.85 (Receivables 18.3m/16.8m, Revenue 80.3m/63.2m) |
| GMI: 0.69 (GM 60.89% / 42.23%) |
| AQI: 0.12 (AQ_t 0.07 / AQ_t-1 0.57) |
| SGI: 1.27 (Revenue 80.3m / 63.2m) |
| TATA: -0.52 (NI 29.3m - CFO 243.7m) / TA 415.5m) |
| Beneish M-Score: -4.28 (Cap -4..+1) = AAA |
What is the price of TBPH shares?
As of February 04, 2026, the stock is trading at USD 19.99 with a total of 292,709 shares traded.
Over the past week, the price has changed by +0.86%, over one month by +8.52%, over three months by +31.34% and over the past year by +111.09%.
Over the past week, the price has changed by +0.86%, over one month by +8.52%, over three months by +31.34% and over the past year by +111.09%.
Is TBPH a buy, sell or hold?
Theravance Biopharma has received a consensus analysts rating of 3.75.
Therefor, it is recommend to hold TBPH.
- StrongBuy: 1
- Buy: 1
- Hold: 2
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the TBPH price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 26.7 | 33.6% |
| Analysts Target Price | 26.7 | 33.6% |
| ValueRay Target Price | 21.8 | 9.1% |
TBPH Fundamental Data Overview January 31, 2026
P/E Trailing = 33.5877
P/E Forward = 15.6495
P/S = 12.0772
P/B = 4.1748
P/EG = -0.05
Revenue TTM = 80.3m USD
EBIT TTM = -27.8m USD
EBITDA TTM = -25.8m USD
Long Term Debt = 44.6m USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 10.9m USD (from shortTermDebt, last quarter)
Debt = 44.6m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -130.2m USD (from netDebt column, last quarter)
Enterprise Value = 685.0m USD (970.1m + Debt 44.6m - CCE 329.7m)
Interest Coverage Ratio = -11.01 (Ebit TTM -27.8m / Interest Expense TTM 2.52m)
EV/FCF = 2.81x (Enterprise Value 685.0m / FCF TTM 243.5m)
FCF Yield = 35.54% (FCF TTM 243.5m / Enterprise Value 685.0m)
FCF Margin = 303.1% (FCF TTM 243.5m / Revenue TTM 80.3m)
Net Margin = 36.53% (Net Income TTM 29.3m / Revenue TTM 80.3m)
Gross Margin = 60.89% ((Revenue TTM 80.3m - Cost of Revenue TTM 31.4m) / Revenue TTM)
Gross Margin QoQ = 59.42% (prev 59.95%)
Tobins Q-Ratio = 1.65 (Enterprise Value 685.0m / Total Assets 415.5m)
Interest Expense / Debt = 1.28% (Interest Expense 573.0k / Debt 44.6m)
Taxrate = 21.0% (US default 21%)
NOPAT = -21.9m (EBIT -27.8m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 9.48 (Total Current Assets 354.7m / Total Current Liabilities 37.4m)
Debt / Equity = 0.19 (Debt 44.6m / totalStockholderEquity, last quarter 232.7m)
Debt / EBITDA = 5.04 (negative EBITDA) (Net Debt -130.2m / EBITDA -25.8m)
Debt / FCF = -0.53 (Net Debt -130.2m / FCF TTM 243.5m)
Total Stockholder Equity = 199.8m (last 4 quarters mean from totalStockholderEquity)
RoA = 7.61% (Net Income 29.3m / Total Assets 415.5m)
RoE = 14.69% (Net Income TTM 29.3m / Total Stockholder Equity 199.8m)
RoCE = -11.36% (EBIT -27.8m / Capital Employed (Equity 199.8m + L.T.Debt 44.6m))
RoIC = -10.98% (negative operating profit) (NOPAT -21.9m / Invested Capital 199.8m)
WACC = 7.37% (E(970.1m)/V(1.01b) * Re(7.66%) + D(44.6m)/V(1.01b) * Rd(1.28%) * (1-Tc(0.21)))
Discount Rate = 7.66% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.95%
Shares Correlation 3-Years: 33.33 | Cagr: 2.49%
[DCF Debug] Terminal Value 73.21% ; FCFF base≈243.5m ; Y1≈159.8m ; Y5≈72.9m
Fair Price DCF = 34.30 (EV 1.61b - Net Debt -130.2m = Equity 1.74b / Shares 50.7m; r=7.37% [WACC]; 5y FCF grow -40.0% → 2.90% )
[DCF Warning] FCF declining rapidly (-40.0%), DCF may be unreliable
EPS Correlation: 58.26 | EPS CAGR: 27.63% | SUE: -2.07 | # QB: 0
Revenue Correlation: 72.12 | Revenue CAGR: 8.06% | SUE: 0.02 | # QB: 0
EPS next Quarter (2026-03-31): EPS=-0.02 | Chg30d=+0.100 | Revisions Net=+1 | Analysts=2
EPS next Year (2026-12-31): EPS=1.69 | Chg30d=+2.100 | Revisions Net=+1 | Growth EPS=+1348.5% | Growth Revenue=-19.4%
P/E Forward = 15.6495
P/S = 12.0772
P/B = 4.1748
P/EG = -0.05
Revenue TTM = 80.3m USD
EBIT TTM = -27.8m USD
EBITDA TTM = -25.8m USD
Long Term Debt = 44.6m USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 10.9m USD (from shortTermDebt, last quarter)
Debt = 44.6m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -130.2m USD (from netDebt column, last quarter)
Enterprise Value = 685.0m USD (970.1m + Debt 44.6m - CCE 329.7m)
Interest Coverage Ratio = -11.01 (Ebit TTM -27.8m / Interest Expense TTM 2.52m)
EV/FCF = 2.81x (Enterprise Value 685.0m / FCF TTM 243.5m)
FCF Yield = 35.54% (FCF TTM 243.5m / Enterprise Value 685.0m)
FCF Margin = 303.1% (FCF TTM 243.5m / Revenue TTM 80.3m)
Net Margin = 36.53% (Net Income TTM 29.3m / Revenue TTM 80.3m)
Gross Margin = 60.89% ((Revenue TTM 80.3m - Cost of Revenue TTM 31.4m) / Revenue TTM)
Gross Margin QoQ = 59.42% (prev 59.95%)
Tobins Q-Ratio = 1.65 (Enterprise Value 685.0m / Total Assets 415.5m)
Interest Expense / Debt = 1.28% (Interest Expense 573.0k / Debt 44.6m)
Taxrate = 21.0% (US default 21%)
NOPAT = -21.9m (EBIT -27.8m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 9.48 (Total Current Assets 354.7m / Total Current Liabilities 37.4m)
Debt / Equity = 0.19 (Debt 44.6m / totalStockholderEquity, last quarter 232.7m)
Debt / EBITDA = 5.04 (negative EBITDA) (Net Debt -130.2m / EBITDA -25.8m)
Debt / FCF = -0.53 (Net Debt -130.2m / FCF TTM 243.5m)
Total Stockholder Equity = 199.8m (last 4 quarters mean from totalStockholderEquity)
RoA = 7.61% (Net Income 29.3m / Total Assets 415.5m)
RoE = 14.69% (Net Income TTM 29.3m / Total Stockholder Equity 199.8m)
RoCE = -11.36% (EBIT -27.8m / Capital Employed (Equity 199.8m + L.T.Debt 44.6m))
RoIC = -10.98% (negative operating profit) (NOPAT -21.9m / Invested Capital 199.8m)
WACC = 7.37% (E(970.1m)/V(1.01b) * Re(7.66%) + D(44.6m)/V(1.01b) * Rd(1.28%) * (1-Tc(0.21)))
Discount Rate = 7.66% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.95%
Shares Correlation 3-Years: 33.33 | Cagr: 2.49%
[DCF Debug] Terminal Value 73.21% ; FCFF base≈243.5m ; Y1≈159.8m ; Y5≈72.9m
Fair Price DCF = 34.30 (EV 1.61b - Net Debt -130.2m = Equity 1.74b / Shares 50.7m; r=7.37% [WACC]; 5y FCF grow -40.0% → 2.90% )
[DCF Warning] FCF declining rapidly (-40.0%), DCF may be unreliable
EPS Correlation: 58.26 | EPS CAGR: 27.63% | SUE: -2.07 | # QB: 0
Revenue Correlation: 72.12 | Revenue CAGR: 8.06% | SUE: 0.02 | # QB: 0
EPS next Quarter (2026-03-31): EPS=-0.02 | Chg30d=+0.100 | Revisions Net=+1 | Analysts=2
EPS next Year (2026-12-31): EPS=1.69 | Chg30d=+2.100 | Revisions Net=+1 | Growth EPS=+1348.5% | Growth Revenue=-19.4%